PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1318090
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1318090
The global protein chip market is experiencing rapid growth, driven by the increasing prevalence of chronic diseases and the demand for advanced treatment options. The evolution of the healthcare sector has been a major influencer for the market's growth, with a growing need for improved disease monitoring and clinical diagnostics. The protein microarray method, which allows for a wide range of analyses in a single experiment, has become a unique selling point, contributing to the market's expansion. Fairfield Market Research's preliminary findings indicate that the high prevalence of cancer worldwide is expected to underpin the growth of the protein chip market.
The outbreak of COVID-19 has highlighted the importance of diagnostics in containing the pandemic, leading to a surge in demand for functional analysis methods. This has made functional analysis a lucrative area of growth as researchers focus on identifying protein-virus interactions through various testing methods.
Cancer, on the other hand, remains a key cause of shortened life expectancy globally. According to the World Health Organization (WHO), there were over 19 million new cancer cases and approximately 10 million cancer-related deaths in 2020. The critical role of protein chips in efficient cancer diagnosis, allowing fast and easy diagnostics with parallel tracking of various protein interactions, targets, small molecules, substrates of protein kinases, and protein-phospholipid interactions, will drive market demand. The broad application scope of protein chips in molecular biology and biochemistry, along with the growing sector of personalized medicine, further enhances their significance in the healthcare industry.
As of 2019, proteomics stood as the leading application area for protein chips, and it is expected to maintain this position in the coming years. Its wide usage in biomedical research and drug discovery is anticipated to be a major revenue generator for the market. Proteomics is deployed in various techniques, including superficial fluid chromatography, chromatography, x-ray crystallography, protein fractionation, spectroscopy, surface plasmon resonance, and electrophoresis. Its ability to offer accurate analysis of in-vivo outcomes makes it an essential tool in the study of tumour resistance mechanisms, disease pathogenesis, and therapeutic developments.
North America is expected to maintain its dominance in the global protein chip market from 2021 to 2026. Well-established biotech companies in the region are projected to invest significantly in research and development of innovative technologies. Europe is also expected to show positive growth due to the rising incidence of cancer and COVID-19, prompting swift action. Analysts anticipate that Asia Pacific will closely follow this development, with protein chip adoption for diagnostics presenting lucrative opportunities in the region.
The competitive landscape of the global protein chip market is shaped by leading players such as Sigma Aldrich Corporation, Affymetrix, Inc., Biacore, SEQUENOM, Inc., Illumina, Inc., Agilent Technologies, HTS Biosystems, EMD Millipore, Life Technologies Corporation, Lumicyte, and Ciphergen Biosystems.